Fundraising Fox
🦊/Companies
Sign in

TippingPoint Biosciences

San Francisco, US · Founded 2022 · 8 employees on LinkedIn · 14 known investors

Find your way into TippingPoint Biosciences

168 people in our graph share verified history with the TippingPoint Biosciences team — schools, employers, funds. One of them is your warm intro.

Joe Horsmanunlockedknows Laura Hsieh · together at University of Washington (overlapped)
×9knows the team · via University of Washington
knows the team · via University of California, San Francisco
knows the team · via Fred Hutch

TippingPoint Biosciences is a therapeutics company developing a drug discovery platform that targets unstructured regions in chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging, with a focus on cancer. Its approach aims to increase specificity, reduce toxicity, and limit drug resistance in oncology treatments.

BiotechDeep TechHealthtech

Founders & leadership

TippingPoint Biosciences was founded in 2022 by Laura Hsieh.

LHLaura Hsieh
Laura HsiehinFounder & CEOLaura Hsieh holds a Ph.D. in Molecular and Cellular Biology from the University of Washington/Fred Hutchinson Cancer Research Center and conducted postdoctoral research at UCSF; she is the founder and CEO of TippingPoint Biosciences, which develops a chromatin-targeting drug discovery platform for oncology.

Investors · 14

FREEFLOWBerkeley
BrightEdgereportedAtlanta
Sazzereported · 2 sourcesBurlingame
SOSVreported · 2 sourcesNew York · $30K – $550K
StoryHousereported · 2 sourcesSisters

Also in the syndicate · 9

American Cancer Society BrightEdgeFreeflow VenturesLKS FundleadPediatric Brain Tumor FoundationSontag FoundationSontag Innovation FundWeCANXEIAYuvaan Tiwari Foundation

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeedApr 2026
    Source ↗
  • Undisclosed amountseed financingMar 2026

    LKS Fund (lead), SOSV (lead), American Cancer Society BrightEdge, Freeflow Ventures, Sazze Partners, Sontag Innovation Fund, StoryHouse Ventures, WeCAN, XEIA

    Source ↗
  • Undisclosed amountpre-seedSep 2024

    BrightEdge, Pediatric Brain Tumor Foundation, Sontag Foundation, Sontag Innovation Fund, Yuvaan Tiwari Foundation

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Ice Miller Helps TippingPoint Biosciences Raise $4.5 Million | Ice Millericemiller.com · Apr 2026TippingPoint Biosciences Secures $4.5 | Signalbasetrysignalbase.com · Apr 2026TippingPoint Biosciences Raises $4.5M in Seed Fundingfinsmes.com · Apr 2026Medpathtrial.medpath.com · Mar 2026TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancerfinance.yahoo.com · Mar 2026TippingPoint Biosciences Closes New Funding to Support Drug for Rare Pediatric Brain Tumorprnewswire.com · Sep 2024

Frequently asked questions

What does TippingPoint Biosciences do?
TippingPoint Biosciences is a therapeutics company developing a drug discovery platform that targets unstructured regions in chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging, with a focus on cancer. Its approach aims to increase specificity, reduce toxicity, and limit drug resistance in oncology treatments.
Who founded TippingPoint Biosciences?
TippingPoint Biosciences was founded by Laura Hsieh in 2022.
Who are TippingPoint Biosciences's investors?
TippingPoint Biosciences's investors include FREEFLOW, BrightEdge, Sazze, SOSV, StoryHouse.
Where is TippingPoint Biosciences headquartered?
TippingPoint Biosciences is headquartered in San Francisco, US.